Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate


Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the

Read the rest here:
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Related Posts